File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Recombinant influenza A virus hemagglutinin HA2 subunit protects mice against influenza A(H7N9) virus infection

TitleRecombinant influenza A virus hemagglutinin HA2 subunit protects mice against influenza A(H7N9) virus infection
Authors
Issue Date2015
PublisherSpringer Wien. The Journal's web site is located at http://www.springer.com/springerwiennewyork/medicine/journal/705
Citation
Archives of Virology, 2015, v. 160 n. 3, p. 777-786 How to Cite?
AbstractA novel avian influenza A(H7N9) virus has emerged to infect humans in eastern China since 2013. An effective vaccine is needed because of the high mortality despite antiviral treatment and intensive care. We sought to develop an effective vaccine for A(H7N9) virus. The HA2 subunit was chosen as the vaccine antigen because it is highly conserved among the human A(H7N9) virus strains. Moreover, in silico analysis predicted two immunogenic regions within the HA2 subunit that may contain potential human B-cell epitopes. The HA2 fragment was readily expressed in Escherichia coli. In BALB/c mice, intraperitoneal immunization with two doses of HA2 with imiquimod (2-dose-imiquimod) elicited the highest geometric mean titer (GMT) of anti-HA2 IgG (12699), which was greater than that of two doses of HA2 without imiquimod (2-dose-no-adjuvant) (6350), one dose of HA2 with imiquimod (1-dose-imiquimod) (2000) and one dose of HA2 without imiquimod (1-dose-no-adjuvant) (794). The titer of anti-HA2 IgG was significantly higher in the 1-dose-imiquimod group than the 1-dose-no-adjuvant group. Although both hemagglutination inhibition titers and microneutralization titers were below 10, serum from immunized mice showed neutralizing activity in a fluorescent focus microneutralization assay. In a viral challenge experiment, the 2-dose-imiquimod group had the best survival rate (100 %), followed by the 2-dose-no-adjuvant group (90 %), the 1-dose-imiquimod group (70 %) and the 1-dose-no-adjuvant group (40 %). The 2-dose-imiquimod group also had significantly lower mean pulmonary viral loads than the 1-dose-imiquimod, 1-dose-no-adjuvant and non-immunized groups. This recombinant A(H7N9)-HA2 vaccine should be investigated as a complement to egg- or cell-based live attenuated or subunit influenza vaccines. © 2015, Springer-Verlag Wien.
Persistent Identifierhttp://hdl.handle.net/10722/214936
ISSN
2015 Impact Factor: 2.255
2015 SCImago Journal Rankings: 1.086
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorTo, KKW-
dc.contributor.authorZhang, AJX-
dc.contributor.authorChan, ASF-
dc.contributor.authorLi, C-
dc.contributor.authorCai, JP-
dc.contributor.authorLau, CCY-
dc.contributor.authorLi, CG-
dc.contributor.authorAkhee, SJ-
dc.contributor.authorWu, WL-
dc.contributor.authorLi, L-
dc.contributor.authorTsang, AKL-
dc.contributor.authorChan, KH-
dc.contributor.authorChen, H-
dc.contributor.authorYuen, KY-
dc.date.accessioned2015-08-21T12:11:19Z-
dc.date.available2015-08-21T12:11:19Z-
dc.date.issued2015-
dc.identifier.citationArchives of Virology, 2015, v. 160 n. 3, p. 777-786-
dc.identifier.issn0304-8608-
dc.identifier.urihttp://hdl.handle.net/10722/214936-
dc.description.abstractA novel avian influenza A(H7N9) virus has emerged to infect humans in eastern China since 2013. An effective vaccine is needed because of the high mortality despite antiviral treatment and intensive care. We sought to develop an effective vaccine for A(H7N9) virus. The HA2 subunit was chosen as the vaccine antigen because it is highly conserved among the human A(H7N9) virus strains. Moreover, in silico analysis predicted two immunogenic regions within the HA2 subunit that may contain potential human B-cell epitopes. The HA2 fragment was readily expressed in Escherichia coli. In BALB/c mice, intraperitoneal immunization with two doses of HA2 with imiquimod (2-dose-imiquimod) elicited the highest geometric mean titer (GMT) of anti-HA2 IgG (12699), which was greater than that of two doses of HA2 without imiquimod (2-dose-no-adjuvant) (6350), one dose of HA2 with imiquimod (1-dose-imiquimod) (2000) and one dose of HA2 without imiquimod (1-dose-no-adjuvant) (794). The titer of anti-HA2 IgG was significantly higher in the 1-dose-imiquimod group than the 1-dose-no-adjuvant group. Although both hemagglutination inhibition titers and microneutralization titers were below 10, serum from immunized mice showed neutralizing activity in a fluorescent focus microneutralization assay. In a viral challenge experiment, the 2-dose-imiquimod group had the best survival rate (100 %), followed by the 2-dose-no-adjuvant group (90 %), the 1-dose-imiquimod group (70 %) and the 1-dose-no-adjuvant group (40 %). The 2-dose-imiquimod group also had significantly lower mean pulmonary viral loads than the 1-dose-imiquimod, 1-dose-no-adjuvant and non-immunized groups. This recombinant A(H7N9)-HA2 vaccine should be investigated as a complement to egg- or cell-based live attenuated or subunit influenza vaccines. © 2015, Springer-Verlag Wien.-
dc.languageeng-
dc.publisherSpringer Wien. The Journal's web site is located at http://www.springer.com/springerwiennewyork/medicine/journal/705-
dc.relation.ispartofArchives of Virology-
dc.rightsThe final publication is available at Springer via http://dx.doi.org/[insert DOI]-
dc.titleRecombinant influenza A virus hemagglutinin HA2 subunit protects mice against influenza A(H7N9) virus infection-
dc.typeArticle-
dc.identifier.emailTo, KKW: kelvinto@hkucc.hku.hk-
dc.identifier.emailZhang, AJX: zhangajx@hkucc.hku.hk-
dc.identifier.emailCai, JP: caijuice@hku.hk-
dc.identifier.emailLau, CCY: laucandy@hku.hk-
dc.identifier.emailAkhee, SJ: akhee@hku.hk-
dc.identifier.emailWu, WL: hazelwu@hkucc.hku.hk-
dc.identifier.emailTsang, AKL: tsangkl@hkucc.hku.hk-
dc.identifier.emailChan, KH: chankh2@hkucc.hku.hk-
dc.identifier.emailChen, H: hlchen@hku.hk-
dc.identifier.emailYuen, KY: kyyuen@hkucc.hku.hk-
dc.identifier.authorityTo, KKW=rp01384-
dc.identifier.authorityZhang, AJX=rp00413-
dc.identifier.authorityChan, KH=rp01921-
dc.identifier.authorityChen, H=rp00383-
dc.identifier.authorityYuen, KY=rp00366-
dc.identifier.doi10.1007/s00705-014-2314-x-
dc.identifier.pmid25616843-
dc.identifier.scopuseid_2-s2.0-84925539772-
dc.identifier.hkuros248298-
dc.identifier.volume160-
dc.identifier.issue3-
dc.identifier.spage777-
dc.identifier.epage786-
dc.identifier.isiWOS:000350295300016-
dc.publisher.placeAustria-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats